Literature DB >> 23587777

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

James A Karlowsky1, Heather J Adam, Marc Desjardins, Philippe R S Lagacé-Wiens, Daryl J Hoban, George G Zhanel.   

Abstract

OBJECTIVES: The purpose of this study was to analyse Canadian national surveillance data, specifically fluoroquinolone resistance, from 2007 to 2011 inclusive, to determine trends in resistance over time and to assess correlations with patient demographic factors.
METHODS: All isolates of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae collected by the 10 sites that participated in the annual CANWARD surveillance studies in each of the 5 years were included in this analysis. A multifactorial logistic regression model was used to determine the variables with significant impact on fluoroquinolone resistance.
RESULTS: The proportion of E. coli isolates resistant to ciprofloxacin increased significantly (P = 0.0005) between 2007 (20.0%) and 2011 (29.2%), although similar increases were not seen in K. pneumoniae, E. cloacae, P. aeruginosa and S. pneumoniae (tested against levofloxacin) (P > 0.05). Among isolates of S. aureus, there was a significant decrease in ciprofloxacin resistance from 34.4% in 2007 to 24.6% in 2011 (P < 0.0001). Resistance to ciprofloxacin was a component of most multidrug-resistant (MDR) phenotypes for E. coli, K. pneumoniae, E. cloacae, P. aeruginosa and S. aureus.
CONCLUSIONS: A significant increase in the percentage of ciprofloxacin-resistant E. coli, primarily among urine isolates, and a significant decrease in the percentage of ciprofloxacin-resistant S. aureus occurred between 2007 and 2011. Notably, MDR isolates were frequently fluoroquinolone resistant for all organisms studied, except S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587777     DOI: 10.1093/jac/dkt025

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals.

Authors:  Lina Zhao; Jing Zhang; Beiwen Zheng; Zeqing Wei; Ping Shen; Sujuan Li; Lanjuan Li; Yonghong Xiao
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

2.  Threading the Needle: Small-Molecule Targeting of a Xenobiotic Receptor to Ablate Escherichia coli Polysaccharide Capsule Expression Without Altering Antibiotic Resistance.

Authors:  Mehreen Arshad; Carlos C Goller; Danielle Pilla; Frank J Schoenen; Patrick C Seed
Journal:  J Infect Dis       Date:  2015-12-15       Impact factor: 5.226

3.  Isolated microorganisms in plastic biliary stents placed for benign and malignant diseases.

Authors:  Paris Basioukas; Antonios Vezakis; Olympia Zarkotou; Georgios Fragulidis; Katerina Themeli-Digalaki; Spyros Rizos; Andreas Polydorou
Journal:  Ann Gastroenterol       Date:  2014

4.  Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016.

Authors:  Wallis Rudnick; Michelle Science; Daniel J G Thirion; Kahina Abdesselam; Kelly B Choi; Linda Pelude; Kanchana Amaratunga; Jeannette L Comeau; Bruce Dalton; Johan Delport; Rita Dhami; Joanne Embree; Yannick Émond; Gerald Evans; Charles Frenette; Susan Fryters; Greg German; Jennifer M Grant; Jennifer Happe; Kevin Katz; Pamela Kibsey; Justin Kosar; Joanne M Langley; Bonita E Lee; Marie-Astrid Lefebvre; Jerome A Leis; Allison McGeer; Heather L Neville; Andrew Simor; Kathryn Slayter; Kathryn N Suh; Alena Tse-Chang; Karl Weiss; John Conly
Journal:  Antimicrob Resist Infect Control       Date:  2020-02-13       Impact factor: 4.887

5.  Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L.

Authors:  Yeonjae Kim; Bongyoung Kim; Seong Heon Wie; Jieun Kim; Moran Ki; Yong Kyun Cho; Seung Kwan Lim; Jin Seo Lee; Ki Tae Kwon; Hyuck Lee; Hee Jin Cheong; Dae Won Park; Seong Yeol Ryu; Moon Hyun Chung; Hyunjoo Pai
Journal:  Antibiotics (Basel)       Date:  2021-01-02

6.  In Vitro Antibiofilm Efficacies of Different Antibiotic Combinations with Zinc Sulfate against Pseudomonas aeruginosa Recovered from Hospitalized Patients with Urinary Tract Infection.

Authors:  Walid Elkhatib; Ayman Noreddin
Journal:  Antibiotics (Basel)       Date:  2014-02-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.